GlassScriptPhysician profile
Melissa D Boothe
NPI 1023298163
$20,550.18
in general payments reported to CMS, 2019-2025
38 companies · $4,916 in 2025
The $4,916 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,965 · 2022: $4,595 · 2023: $4,683 · 2024: $4,391 · 2025: $4,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,835.97 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,205.14 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $2,059.17 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $1,717.13 | 2021-2025 | |
| Janssen Biotech, INC. | $1,272.55 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,270.26 | 2021-2025 | |
| Lilly USA, LLC | $1,143.80 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $1,114.79 | 2021-2025 | Bimzelx, Cimzia |
| Medimetriks Pharmaceuticals, INC. | $1,109.57 | 2022-2025 | Clindacin Etz, Neo-Synalar, Neuac |
| Pfizer INC. | $1,032.09 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,013.00 | 2022-2025 | Sotyktu |
| Amgen INC. | $962.43 | 2021-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $836.81 | 2021-2024 | Adbry |
| Galderma Laboratories, L.P. | $733.92 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Dermavant Sciences, INC. | $583.37 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $563.58 | 2022-2025 | Dupixent, Libtayo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $438.75 | 2022-2025 | |
| Incyte Corporation | $433.51 | 2022-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $415.33 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $396.32 | 2023-2025 | Zoryve |
| Epi Health, LLC | $274.72 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.88 | 2022-2025 | Spevigo |
| Botanix Sb INC | $184.47 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.03 | 2023-2025 | Cabtreo, Jublia |
| Fresenius Kabi USA, LLC | $71.14 | 2023-2024 | Idacio |
| Biofrontera INC. | $57.50 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Convatec INC. | $53.21 | 2023-2024 | |
| Kerecis Limited | $48.66 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Verrica Pharmaceuticals INC. | $43.94 | 2023-2025 | Ycanth |
| Sandoz INC. | $36.99 | 2021-2024 | Hyrimoz |
| Lnhc, INC | $32.13 | 2025 | Zelsuvmi |
| Almirall LLC | $31.07 | 2024 | Klisyri |
| Cipher Pharmaceuticals US LLC | $27.41 | 2025 | Natroba, Spinosad |
| Nobelpharma America, LLC | $25.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.35 | 2022 | |
| Mayne Pharma Commercial LLC | $18.33 | 2023 | |
| Organogenesis INC. | $15.00 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $11.85 | 2021 | |
| Organon LLC | $9.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Boothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.